Real-time Imaging of the Dynamics of Death Receptors and Therapeutics That Overcome TRAIL Resistance in Tumors

Overview

Journal Oncogene

Specialties Molecular Biology
Oncology

Date 2012 Jul 25

PMID 22824792

Citations 26

Authors

T Bagci-Onder

A Agarwal

D Flusberg

S Wanningen

P Sorger

K Shah

Affiliations

Soon will be listed here.

Abstract

Tumor necrosis factor related apoptosis-inducing ligand (TRAIL) induces apoptosis specifically in tumor cells and its efficacy has been tested in pre-clinical models by delivering it systemically as a purified ligand or via engineered stem cells (SC). However, about 50% of tumor lines are resistant to TRAIL and overcoming TRAIL resistance in aggressive tumors, such as glioblastoma-multiforme (GBM), and understanding the molecular dynamics of TRAIL-based combination therapies are critical to broadly use TRAIL as a therapeutic agent. In this study, we developed death receptor (DR)4/5-reporters that offer an imaging-based platform to identify agents that act in concert with a potent, secretable variant of TRAIL (S-TRAIL) by monitoring changes in DR4/5 expression. Utilizing these reporters, we show a differential regulation of DR4/5 when exposed to a panel of clinically relevant agents. A histone deacetylase inhibitor, MS-275, resulted in upregulation of DR4/5 in all GBM cell lines, and these changes could be followed in real time both in vitro and in vivo in mice bearing tumors and they correlated with increased TRAIL sensitivity. To further assess the dynamics of combinatorial strategies that overcome resistance of tumors to SC released S-TRAIL, we also engineered tumor cells to express live-cell caspase-reporters and SCs to express S-TRAIL. Utilizing DR4/5 and caspase reporters in parallel, we show that MS-275 sensitizes TRAIL-resistant GBM cells to stem cell (SC) delivered S-TRAIL by changing the time-to-death in vitro and in vivo. This study demonstrates the effectiveness of a combination of real-time reporters of TRAIL-induced apoptosis pathway in evaluating the efficacy of SC-TRAIL-based therapeutics and may have implications in targeting a broad range of cancers.

Citing Articles

A lentiviral toolkit to monitor airway epithelial cell differentiation using bioluminescence.

Orr J, Laali A, Durrenberger P, Lazarus K, El Mdawar M, Janes S Am J Physiol Lung Cell Mol Physiol. 2024; 327(4):L587-L599.

PMID: 39137525 PMC: 11482462. DOI: 10.1152/ajplung.00047.2024.

Epigenetic-focused CRISPR/Cas9 screen identifies (absent, small, or homeotic)2-like protein (ASH2L) as a regulator of glioblastoma cell survival.

Ozyerli-Goknar E, Kala E, Aksu A, Bulut I, Cingoz A, Nizamuddin S Cell Commun Signal. 2023; 21(1):328.

PMID: 37974198 PMC: 10652464. DOI: 10.1186/s12964-023-01335-6.

Use of FLOSEAL® as a scaffold and its impact on induced neural stem cell phenotype, persistence, and efficacy.

Bomba H, Carey-Ewend A, Sheets K, Valdivia A, Goetz M, Findlay I Bioeng Transl Med. 2022; 7(2):e10283.

PMID: 35600639 PMC: 9115686. DOI: 10.1002/btm2.10283.

Poly(beta-amino ester) nanoparticles enable tumor-specific TRAIL secretion and a bystander effect to treat liver cancer.

Vaughan H, Zamboni C, Radant N, Bhardwaj P, Lechtich E, Hassan L Mol Ther Oncolytics. 2021; 21:377-388.

PMID: 34189258 PMC: 8208964. DOI: 10.1016/j.omto.2021.04.004.

Drug Repositioning Screen on a New Primary Cell Line Identifies Potent Therapeutics for Glioblastoma.

Senbabaoglu F, Aksu A, Cingoz A, Seker-Polat F, Borklu-Yucel E, Solaroglu I Front Neurosci. 2021; 14:578316.

PMID: 33390879 PMC: 7773901. DOI: 10.3389/fnins.2020.578316.

References

Sasportas L, Kasmieh R, Wakimoto H, Hingtgen S, van de Water J, Mohapatra G . Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc Natl Acad Sci U S A. 2009; 106(12):4822-7. PMC: 2660771. DOI: 10.1073/pnas.0806647106. View

Sung B, Park B, Yadav V, Aggarwal B . Celastrol, a triterpene, enhances TRAIL-induced apoptosis through the down-regulation of cell survival proteins and up-regulation of death receptors. J Biol Chem. 2010; 285(15):11498-507. PMC: 2857028. DOI: 10.1074/jbc.M109.090209. View

Kim M, Moon D, Kang C, Kwon T, Choi Y, Kim G . beta-Ionone enhances TRAIL-induced apoptosis in hepatocellular carcinoma cells through Sp1-dependent upregulation of DR5 and downregulation of NF-kappaB activity. Mol Cancer Ther. 2010; 9(4):833-43. DOI: 10.1158/1535-7163.MCT-09-0610. View

Ashkenazi A, Herbst R . To kill a tumor cell: the potential of proapoptotic receptor agonists. J Clin Invest. 2008; 118(6):1979-90. PMC: 2396896. DOI: 10.1172/JCI34359. View

Ashkenazi A . Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat Rev Drug Discov. 2008; 7(12):1001-12. DOI: 10.1038/nrd2637. View

Hingtgen S, Kasmieh R, van de Water J, Weissleder R, Shah K . A novel molecule integrating therapeutic and diagnostic activities reveals multiple aspects of stem cell-based therapy. Stem Cells. 2010; 28(4):832-41. PMC: 3021283. DOI: 10.1002/stem.313. View

Spencer S, Gaudet S, Albeck J, Burke J, Sorger P . Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis. Nature. 2009; 459(7245):428-32. PMC: 2858974. DOI: 10.1038/nature08012. View

Liu X, Yue P, Chen S, Hu L, Lonial S, Khuri F . The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells. Cancer Res. 2007; 67(10):4981-8. DOI: 10.1158/0008-5472.CAN-06-4274. View

Booth N, Sayers T, Brooks A, Thomas C, Jacobsen K, Goncharova E . A cell-based high-throughput screen to identify synergistic TRAIL sensitizers. Cancer Immunol Immunother. 2008; 58(8):1229-44. PMC: 3168559. DOI: 10.1007/s00262-008-0637-8. View

10.

McDermott U, Pusapati R, Christensen J, Gray N, Settleman J . Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency. Cancer Res. 2010; 70(4):1625-34. PMC: 3057521. DOI: 10.1158/0008-5472.CAN-09-3620. View

11.

Bagci-Onder T, Wakimoto H, Anderegg M, Cameron C, Shah K . A dual PI3K/mTOR inhibitor, PI-103, cooperates with stem cell-delivered TRAIL in experimental glioma models. Cancer Res. 2010; 71(1):154-63. DOI: 10.1158/0008-5472.CAN-10-1601. View

12.

Dhandapani L, Yue P, Ramalingam S, Khuri F, Sun S . Retinoic acid enhances TRAIL-induced apoptosis in cancer cells by upregulating TRAIL receptor 1 expression. Cancer Res. 2011; 71(15):5245-54. PMC: 3151668. DOI: 10.1158/0008-5472.CAN-10-4180. View

13.

Baritaki S, Huerta-Yepez S, Sakai T, Spandidos D, Bonavida B . Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1. Mol Cancer Ther. 2007; 6(4):1387-99. DOI: 10.1158/1535-7163.MCT-06-0521. View

14.

Wood T, Dalili S, Simpson C, Sukhai M, Hurren R, Anyiwe K . Selective inhibition of histone deacetylases sensitizes malignant cells to death receptor ligands. Mol Cancer Ther. 2010; 9(1):246-56. DOI: 10.1158/1535-7163.MCT-09-0495. View

15.

Crosswell H, Dasgupta A, Alvarado C, Watt T, Christensen J, De P . PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cells. BMC Cancer. 2009; 9:411. PMC: 2790467. DOI: 10.1186/1471-2407-9-411. View

16.

Albeck J, Burke J, Aldridge B, Zhang M, Lauffenburger D, Sorger P . Quantitative analysis of pathways controlling extrinsic apoptosis in single cells. Mol Cell. 2008; 30(1):11-25. PMC: 2858979. DOI: 10.1016/j.molcel.2008.02.012. View

17.

Nagar S . Pharmacokinetics of anti-cancer drugs used in breast cancer chemotherapy. Adv Exp Med Biol. 2010; 678:124-32. DOI: 10.1007/978-1-4419-6306-2_16. View

18.

Yoshida T, Shiraishi T, Nakata S, Horinaka M, Wakada M, Mizutani Y . Proteasome inhibitor MG132 induces death receptor 5 through CCAAT/enhancer-binding protein homologous protein. Cancer Res. 2005; 65(13):5662-7. DOI: 10.1158/0008-5472.CAN-05-0693. View

19.

Wiezorek J, Holland P, Graves J . Death receptor agonists as a targeted therapy for cancer. Clin Cancer Res. 2010; 16(6):1701-8. DOI: 10.1158/1078-0432.CCR-09-1692. View

20.

Shah K, Bureau E, Kim D, Yang K, Tang Y, Weissleder R . Glioma therapy and real-time imaging of neural precursor cell migration and tumor regression. Ann Neurol. 2004; 57(1):34-41. DOI: 10.1002/ana.20306. View